公开(公告)号：WO1996019500A1

公开(公告)日：1996-06-27

申请号：PCT/US1995016613

申请日：1995-12-18

Applicant: UNIVERSITY OF WASHINGTON

Inventor： UNIVERSITY OF WASHINGTON ,  MARCOVINA, Santica, M. ,  ALBERS, John, J.

IPC: C07K16/00

CPC classification number: G01N33/92 ,  C07K16/18

Abstract: The present invention relates to monoclonal antibodies and a method for the quantification of apolipoprotein(a) and lipoprotein(a) present in human body fluids. The method is not sensitive to the presence of plasminogen or the apo(a) kringle 4 repeats. The assay involves the addition of the test sample to an immobilized anti-apo(a) antibody and forming a first immobilized complex of apolipoprotein(a)/anti-apo(a) first antibody, contacting first immune complex with an anti-apo(a) monoclonal antibody specific for apo(a) with non crossreactivity to plasminogen and which does not identify the kringle 4 type 2 apo(a) repeats and thereafter quantitating apo(a) based on the amount of bound anti-apo(a) monoclonal antibody. Immobilized goat or rabbit anti-human apo(a) antibody can be employed as the first capture antibody and the mouse anti-apo(a) monoclonal antibody as second antibody. The amount of anti-apo(a) monoclonal antibody bound is quantitated through binding of a third antibody enzyme conjugant, e.g., goat anti-mouse antibody/horseradish peroxidase (HRP) conjugate, followed by reaction with a suitable substrate such as o-phenylenediamine dihydrochloride.

Abstract translation: 本发明涉及单克隆抗体和定量存在于人体液中的载脂蛋白（a）和脂蛋白（a）的方法。 该方法对纤溶酶原或apo（a）kringle 4重复的存在不敏感。 测定包括将测试样品加入到固定的抗apo（a）抗体中，并形成第一个固定的载脂蛋白（a）/抗apo（a）第一抗体的复合物，使第一免疫复合物与抗apo a）对纤维蛋白溶酶原具有非交叉反应性的apo（a）特异性的单克隆抗体，其不识别kringle 4型2载脂蛋白（a）重复，然后基于结合的抗apo（a）单克隆抗体的量来定量apo（a） 抗体。 可以使用固定化的山羊或兔抗人apo（a）抗体作为第一抗体和小鼠抗apo（a）单克隆抗体作为第二抗体。 通过结合第三抗体酶缀合物例如山羊抗小鼠抗体/辣根过氧化物酶（HRP）缀合物，然后与合适的底物例如邻苯二胺反应来定量结合的抗apo（a）单克隆抗体的量 二盐酸盐。

公开(公告)号：WO1995024430A2

公开(公告)日：1995-09-14

申请号：PCT/US1995002638

申请日：1995-03-03

Applicant: UNIVERSITY OF WASHINGTON ,  ALCON LABORATORIES, INC.

Inventor： UNIVERSITY OF WASHINGTON ,  ALCON LABORATORIES, INC. ,  HOFFMAN, Allan, S. ,  CHEN, Guohua ,  YORK, Billie, M.

IPC: C08F00/00

CPC classification number: A61K9/0014 ,  A61K8/91 ,  A61K9/2027 ,  A61K9/2031 ,  A61K47/32 ,  A61K47/34 ,  A61K2800/54 ,  A61Q19/00 ,  C08F265/10 ,  C08F291/00 ,  C08G81/00 ,  C08L71/02 ,  C08F220/06 ,  C08L2666/24 ,  C08L2666/04

Abstract: There is disclosed block and graft copolymers which, in one embodiment, contain both a temperature-sensitive polymer component and a pH-sensitive polymer component, and the use of such copolymers for topical drug delivery to a treatment area. The block and graft copolymers may be physically mixed with one or more drugs to form a copolymer-drug mixture. This mixture may be applied to the treatment as solid particles suspended in a pharmaceutically acceptable carrier, or as a liquid which gels upon contact with the treatment area. Upon contact with the treatment area, the pH-sensitive polymer component hydrates and swells, thereby causing release of the drug from the mixture. In addition, such hydration and swelling causes the pH-sensitive polymer component to adhere to the tissue of the treatment area, thus prolonging contact time. The temperature-sensitive polymer component resists hydration and swelling of the mixture, thereby imparting a sustained and controlled release of the drug to the treatment area. In another embodiment of this invention, bloc and graft copolymers, and hydrogels thereof, are disclosed having broad industrial applicability.

Abstract translation: 公开了一种在一个实施方案中含有温度敏感性聚合物组分和pH敏感性聚合物组分的嵌段和接枝共聚物，以及这些共聚物用于局部药物递送至处理区域的用途。 嵌段和接枝共聚物可以与一种或多种药物物理混合以形成共聚物 - 药物混合物。 该混合物可以作为悬浮在药学上可接受的载体中的固体颗粒或作为与处理区域接触时凝胶化的液体施用于处理。 与处理区域接触时，pH敏感的聚合物组分水合并溶胀，从而导致药物从混合物中释放出来。 此外，这种水合和溶胀导致pH敏感聚合物组分粘附到处理区域的组织，从而延长接触时间。 温度敏感的聚合物组分抵抗混合物的水合和溶胀，由此赋予药物持续且受控的释放到治疗区域。 在本发明的另一个实施方案中，公开了具有广泛的工业实用性的团和接枝共聚物及其水凝胶。

公开(公告)号：WO1995021626A1

公开(公告)日：1995-08-17

申请号：PCT/US1995001829

申请日：1995-02-09

Applicant: UNIVERSITY OF WASHINGTON

Inventor： UNIVERSITY OF WASHINGTON ,  KAUSHANSKY, Kenneth

IPC: A61K38/19

CPC classification number: G01N33/5011 ,  A61K38/1816 ,  A61K38/196 ,  A61K2035/124 ,  C07K14/47 ,  C07K14/705 ,  C07K14/715 ,  C12N5/0642 ,  C12N2501/145 ,  C12N2501/22 ,  G01N33/5005 ,  G01N33/5008 ,  A61K2300/00

Abstract: Methods for stimulating erythropoiesis using hematopoietic proteins are provided. The methods provided may be used to stimulate erythropoiesis in bone marrow and peripheral blood cells and in vitro and in vivo. In addition, methods for treatment of thrombocytopenia and anemia in patients are disclosed.

Abstract translation: 提供了使用造血蛋白刺激红细胞生成的方法。 所提供的方法可用于刺激骨髓和外周血细胞中的体外和体内的红细胞生成。 另外，公开了治疗患者血小板减少症和贫血的方法。

公开(公告)号：WO1995004268A1

公开(公告)日：1995-02-09

申请号：PCT/US1994008430

申请日：1994-07-25

Applicant: UNIVERSITY OF WASHINGTON

Inventor： UNIVERSITY OF WASHINGTON ,  JOHNSON, Roger, H. ,  NELSON, Alan, C.

IPC: G01N23/087

CPC classification number: G01N23/046 ,  A61B6/583 ,  G01N2223/419 ,  G21K7/00 ,  Y10S378/901

Abstract: A microtomographic system (10) for generating high-resolution, three dimensional images of a specimen (16) is disclosed. The microtomograph system includes an x-ray generator (12) that produces an x-ray beam (14), a specimen holder (18) that holds the specimen in the beam, and an x-ray detector (20) that measures the attenuation of the beam through the specimen. Two projections of each view of the specimen are made with this microtomographic system. Each projection is made with a different intensity x-ray beam. After the projections of one view of the specimen are made, the specimen is rotated on the specimen holder and another set of projections are made. The projections of each view of the specimen are analyzed together to provide a quantitative indication of the phase fraction of the material comprising the specimen. The projections of the different views are combined to provide a three-dimensional image of the specimen.

Abstract translation: 公开了一种用于产生样本（16）的高分辨率三维图像的微图系统（10）。 显微图像系统包括产生X射线束（14）的X射线发生器（12），将样本保持在束中的样本保持器（18）和测量衰减的X射线检测器（20） 的光束通过样品。 用该微图系统制作样本的每个视图的两个突出部分。 每个投影都由不同强度的X射线束制成。 在制作样本的一个视图的突起之后，将样本在样本保持器上旋转，并且制作另一组突起。 一起分析样品的每个视图的突起，以提供包含样品的材料的相分数的定量指示。 组合不同视图的投影以提供样本的三维图像。

公开(公告)号：WO1994022473A1

公开(公告)日：1994-10-13

申请号：PCT/US1994003532

申请日：1994-03-30

Applicant: UNIVERSITY OF WASHINGTON

Inventor： UNIVERSITY OF WASHINGTON ,  HO, Rodney, Jin, Yong ,  FALTYNEK, Connie, Rene

IPC: A61K39/00

CPC classification number: A61K39/39 ,  A61K39/12 ,  A61K39/21 ,  A61K39/245 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55527 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/6018 ,  C12N2710/16634 ,  C12N2740/16134 ,  A61K38/20 ,  A61K2300/00

Abstract: Vaccine compositions and methods which include interleukin-7 (IL-7) improve the potency of the vaccine formulation in a mammalian host. The methods relate to administering a therapeutically effective amount of a vaccine and a potency-improving amount of IL-7. Preferably the IL-7 is dissolved or dispersed in a pharmaceutically acceptable carrier, such as a lipid dispersion. IL-7 provides enhanced vaccine potency for preventing microbial infections, especially viral infections (e.g. herpes simplex virus (HSV) and the human immunodeficiency virus (HIV)), but can also be used to enhance the potency of vaccines against fungi, yeast, bacteria and protozoa. In preferred embodiments, the viral antigen component of the vaccine and IL-7 combination is recombinant HIV envelope protein or HSV glycoprotein D.

Abstract translation: 包括白细胞介素-7（IL-7）的疫苗组合物和方法提高了哺乳动物宿主中疫苗制剂的效力。 所述方法涉及施用治疗有效量的疫苗和改善剂量的IL-7。 优选地，IL-7溶解或分散在药学上可接受的载体中，例如脂质分散体。 IL-7提供了增强的疫苗效力，用于预防微生物感染，特别是病毒感染（例如单纯疱疹病毒（HSV）和人类免疫缺陷病毒（HIV））），但也可用于增强针对真菌，酵母，细菌的疫苗的效力 和原生动物。 在优选的实施方案中，疫苗和IL-7组合的病毒抗原成分是重组HIV包膜蛋白或HSV糖蛋白D.

公开(公告)号：WO1994015962A2

公开(公告)日：1994-07-21

申请号：PCT/US1993012692

申请日：1993-12-30

Applicant: ZYMOGENETICS, INC. ,  UNIVERSITY OF WASHINGTON

Inventor： ZYMOGENETICS, INC. ,  UNIVERSITY OF WASHINGTON ,  LABROO, Virender ,  SASAKI, Tomikazu

IPC: C07K07/36

CPC classification number: C07K14/57527 ,  A61K38/00 ,  C07K14/585

Abstract: Derivatized calcitonin molecules, pharmaceutical compositions comprising derivatized calcitonins, and methods of reducing serum calcium in a patient using the derivatized calcitonins are disclosed. The molecules are characterized by a derivatized amino terminus formed by combining a calcitonin with a cyclic, polycyclic or heterocyclic moiety. Multimeric forms of the molecules are also disclosed.

Abstract translation: 公开了衍生降钙素分子，包含衍生的降钙素的药物组合物和使用衍生的降钙素降低患者血清钙的方法。 分子的特征在于通过将降钙素与环状，多环或杂环部分组合形成的衍生化氨基末端。 还公开了分子的多聚体形式。

公开(公告)号：WO1994014063A1

公开(公告)日：1994-06-23

申请号：PCT/US1993012149

申请日：1993-12-14

Applicant: UNIVERSITY OF WASHINGTON ,  CLARK, John, I. ,  VAEZY, Shahram

Inventor： UNIVERSITY OF WASHINGTON

IPC: G01N33/483

CPC classification number: G01N33/4833 ,  G06T7/48 ,  G06T2207/10061 ,  G06T2207/10088 ,  G06T2207/20056 ,  G06T2207/30024

Abstract: A system (10) is disclosed for use in detecting and analyzing cell and tissue microstructure as part of the diagnosis of a variety of pathological conditions, including cataracts, as well as aging, disease and certain traumatic events. The system includes a data input system (12), which may produce data regarding the microstructure to be evaluated either invasively or noninvasively. An electron microscope (20) may be employed to collect data regarding the microstructure of any tissue to be evaluated for the existence of a pathological condition. The system (12) also includes a computer (14) programmed to analyze the output of the data collection system by using signal processing techniques that are applicable to the data output characterizing the nonrandom microstructure. These techniques include fractal analysis, oscillatory analysis, and a modified Fourier/fractal analysis. The outcome of the signal processing is then compared to empirical data to effect a diagnosis.

Abstract translation: 公开了一种系统（10），用于检测和分析细胞和组织微结构，作为诊断多种病理状况（包括白内障）以及衰老，疾病和某些创伤性事件的一部分。 该系统包括数据输入系统（12），其可以产生关于要被侵入或非侵入性地评估的微结构的数据。 可以使用电子显微镜（20）来收集关于待评估的任何组织的微观结构的病理状态的存在的数据。 系统（12）还包括计算机（14），其被编程为通过使用适用于表征非随机微结构的数据输出的信号处理技术来分析数据收集系统的输出。 这些技术包括分形分析，振荡分析和改进的傅里叶/分形分析。 然后将信号处理的结果与经验数据进行比较以进行诊断。

公开(公告)号：WO1993023571A1

公开(公告)日：1993-11-25

申请号：PCT/US1993004458

申请日：1993-05-12

Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER ,  UNIVERSITY OF WASHINGTON ,  THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE ... ,  PLON, Sharon, E. ,  GROUDINE, Mark, T. ,  HARTWELL, Leland, H. ,  WEINERT, Ted, A.

Inventor： FRED HUTCHINSON CANCER RESEARCH CENTER ,  UNIVERSITY OF WASHINGTON ,  THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE ...

IPC: C12Q01/68

CPC classification number: C07K14/47 ,  C12Q1/6876 ,  C12Q2600/158 ,  G01N33/5011

Abstract: Human checkpoint huCDC34, huRAD9?compA?, and huRAD9?compB? cDNAs are shown in Figures 1, 2 and 3. A method for isolating a human checkpoint cDNA that is capable of restoring growth at a restrictive temperature in a yeast test cell, wherein the yeast test cell comprises a genome having a first gene that forms a DNA strand break at a restrictive temperature and a second gene that fails to induce a cell cycle arrest in response to the DNA strand break, whereby the growth of the yeast test cell is inhibited at the restrictive temperature, the method comprising the steps of: obtaining a human cDNA library comprising a plurality of human cDNA clones; inserting the human cDNA clones individually into plasmid vectors comprising a selectable marker gene; transforming a culture of the yeast test cells with the plasmid vectors from the preceding step; selecting for yeast test cells transformed with the selectable marker gene; growing the selected transformants at the restrictive temperature and isolating a candidate transformant capable of growing at the restrictive temperature; and identifying the human cDNA carried by the candidate transformant as a human checkpoint cDNA by sequencing the human cDNA carried by the candidate transformant and determining that the human cDNA is less than 50 % homologous with both the first gene and the second gene.

Abstract translation: 人检查点huCDC34，huRAD9？compA？和huRAD9？compB？ cDNA示于图1,2和3.一种用于分离能够在酵母测试细胞中以限制性温度恢复生长的人类检测点cDNA的方法，其中酵母测试细胞包含具有形成第一基因的基因组 DNA链在限制性温度下断裂，第二种基因不能诱导针对DN​​A链断裂的细胞周期停滞，从而在限制性温度下抑制酵母测试细胞的生长，该方法包括以下步骤：获得 包含多个人cDNA克隆的人cDNA文库; 将人cDNA克隆单独插入包含选择标记基因的质粒载体中; 用前述步骤的质粒载体转化酵母测试细胞的培养物; 选择用可选择标记基因转化的酵母测试细胞; 在限制性温度下生长所选择的转化体并分离能够在限制温度下生长的候选转化体; 以及通过对候选转化体携带的人cDNA进行测序并确定人cDNA与第一基因和第二基因两者都小于50％同源性来鉴定候选转化体携带的人cDNA作为人检测点cDNA。

公开(公告)号：WO1998024479A1

公开(公告)日：1998-06-11

申请号：PCT/US1997021398

申请日：1997-12-02

Applicant: SOMATIX THERAPY CORPORATION ,  UNIVERSITY OF WASHINGTON ,  SNYDER, Richard ,  DANOS, Olivier ,  COHEN, Lawrence ,  KAY, Mark ,  THOMPSON, Arthur, R.

Inventor： SOMATIX THERAPY CORPORATION ,  UNIVERSITY OF WASHINGTON

IPC: A61K48/00

CPC classification number: C12N15/86 ,  A61K38/4846 ,  A61K48/00 ,  C12N2750/14143

Abstract: The instant invention provides methods of expressing polynucleotides in the cells of the liver comprising administering viral particles comprising a recombinant AAV vector into a mammal, preferably a human.

Abstract translation: 本发明提供了在肝细胞中表达多核苷酸的方法，包括将包含重组AAV载体的病毒颗粒施用于哺乳动物，优选人中。

公开(公告)号：WO1997042620A1

公开(公告)日：1997-11-13

申请号：PCT/US1997007419

申请日：1997-05-02

Applicant: UNIVERSITY OF WASHINGTON

Inventor： UNIVERSITY OF WASHINGTON ,  WELLS, Maxwell, J. ,  MANDEVILLE, Jon ,  FURNESS, Thomas, A. ,  PULKKA, Aaron, K. ,  LAMAR, Michael ,  ATEN, Jason

IPC: G09G05/00

CPC classification number: G06F3/011

Abstract: A motion control device (16) for a virtual environment, robot or vehicle. The controller allows the user enough movement in the real world to create a sense of reality and presence in the virtual environment. A user is positioned on a surface and is able to move within multiple control regions (24, 26). The virtual environment, robot or vehicle responds differently to inputs from a first control region (24) than from a second control region (26).

Abstract translation: 一种用于虚拟环境，机器人或车辆的运动控制装置（16）。 控制器允许用户在现实世界中有足够的运动，以在虚拟环境中创造出现实感和存在感。 用户位于表面上并且能够在多个控制区域（24,26）内移动。 虚拟环境，机器人或车辆对来自第一控制区域（24）的输入的响应不同于来自第二控制区域（26）的输入。